Phase 4 N=288 Extended Release Naltrexone for Opioid-Dependent Youth
Drug Dependence
Primary: Opioid Use at 6 Month Follow-up — 19.63; 18.42 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=14 Neural Correlates In Mild Alzheimer's Disease
Alzheimer's Disease
Primary: Percent Change From Baseline to Week 12 Based on Hippocampus Connectivity Index (HCI) — 7.47 percent change
Phase 4 N=184 Preoperative Antibiotics for Carpal Tunnel Release Surgery
Carpal Tunnel Syndrome
Primary: Number of Participants With Surgical Site Infection — 0; 0; 0 Participants
Phase 4 N=80 A Pilot Trial of Perinatal Depression Treatment in HIV Infected Women
Perinatal Depression · HIV-1-infection
Primary: Number of Women Approached Who Agreed to Pre-Screening With EPDS — 240 Participants
Phase 4 N=32 A Study on the Safety of Tranexamic Acid for the Chronic Subdural Hematoma Population
Subdural Hematoma
Primary: Number of Participants With Medication Related (Thromboembolic) Complications — 0 Participants
Phase 4 N=5,276 Tailored Antiplatelet Therapy Following PCI
Coronary Artery Disease · Acute Coronary Syndrome · Stenosis
Primary: Occurrence of the a Major Adverse Cardiovascular Event in Subjects Identified as CPY2C19 LOF Carriers by TaqMan. — 35; 54 Participants
Phase 4 N=103 Evaluation of Abdominal Wall Block With Liposomal Bupivacaine for Post-Operative Analgesia in Donor Nephrectomy
Pain, Postoperative · Analgesics, Opioid · Analgesics, Non-Narcotic
Primary: Change in Pain Score — 4.20; 4.62 score on a scale
Phase 4 N=10 Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C
Chronic Kidney Disease · Chronic Hepatitis C
Primary: Average Change in Urine Tumor Necrosis Factor (TNF)-Alpha From Baseline to Post-treatment — -0.05 ng/g
Phase 4 N=38 Rifaximin Therapy in Chronic Kidney Disease
Chronic Kidney Disease
Primary: Change in Serum Trimethylamine N-oxide (TMAO) — -3.9; 0.5 uM
Phase 4 N=17 Pneumococcal Vaccines in Patients With Asthma
Asthma
Primary: Total Anti-pneumococcal IgG Levels at Baseline, Week 0, Week 8 and Week 16 — 109.8; 53.9; 142.3; 53.9 mcg/dL
Phase 4 N=140 The Efficacy of Intravenous Acetaminophen During Perioperative Neurosurgery Period
Craniotomy · Brain Surgery
Primary: Opioid Requirement After Surgery — 10; 4 Participants
Phase 4 N=78 Prevention of Persistent Opioid Use in Mothers
Opioid Use · Postpartum Disorder · Chronic Pain Syndrome
Primary: Time to Opioid Cessation as a Measure of Opioid Utilization — 2; 2 weeks
Phase 4 N=10 The Role of Estrogen in Luteinizing Hormone Surge and Ovulation
Ovulation Disorder · Ovarian Cysts
Primary: Number of Participants With Progesterone Level Greater Than 1.5 ng/mL — 9; 10 Participants
Phase 4 N=273 Liraglutide Hospital Discharge Trial
Type 2 Diabetes
Primary: Glycemic Control at Hospital Discharge and 6 Months Follow up — 8.3; 8.4; 7.13; 7.68 % (mmol/mol)
Phase 4 N=80 Effect of Vascepa on Improving Coronary Atherosclerosis in People With High Triglycerides Taking Statin Therapy
Hypertriglyceridemia
Primary: Progression Rates of Low Attenuation Plaque Under Influence of Vascepa as Compared to Placebo as a Change Between Two or More Time Points — -0.3; 0.9 volume in mm cubed